Soleno Therapeutics Inc Randomized Withdrawal Period of Study C602 Topline Results Call Transcript
Greetings. Welcome to Soleno Therapeutics randomized withdrawal period of Study C602 topline results. (Operator Instructions) Please note this conference is being recorded.
At this time, I'll now turn the floor over to Brian Ritchie with LifeSci Advisors. Brian, you may now begin.
Thank you, operator. Thank you all for joining us this morning. With me on today's call are Soleno's Chief Executive Officer, Dr. Anish Bhatnagar; the company's Chief Financial Officer, Jim Mackaness; and Dr. Jennifer Miller, Professor of Pediatrics in the Division of Endocrinology at the University of Florida. This morning, Soleno issued a news release announcing top-line results from the company's randomized withdrawal period of Study C602, evaluating DCCR tablets for patients with Prader-Willi syndrome.
Please note that certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that, during this call, Soleno management
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |